Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(9): e24661.
Published online 2011 Sep 16. doi:  10.1371/journal.pone.0024661
PMCID: PMC3174976

Knowledge, Perceptions and Information about Hormone Therapy (HT) among Menopausal Women: A Systematic Review and Meta-Synthesis

Virginia J. Vitzthum, Editor



The use of hormone therapy (HT) by menopausal women has declined since the Women's Health Initiative randomized trial (WHI) in 2002 demonstrated important harms associated with long-term use. However, how this information has influenced women's knowledge and attitudes is uncertain. We aimed to evaluate the attitudes and perceptions towards HT use, as well as specific concerns and information sources on HT since the WHI trial.


We did a systematic review to assess the attitudes and knowledge towards HT in women, and estimate the magnitude of the issue by pooling across the studies. Using meta-synthesis methods, we reviewed qualitative studies and surveys and performed content analysis on the study reports. We pooled quantitative studies using a random-effects meta-analysis. We analyzed 11 qualitative studies (n = 566) and 27 quantitative studies (n = 39251). Positive views on HT included climacteric symptom control, prevention of osteoporosis and a perceived improvement in quality of life. Negative factors reported included concerns about potential harmful effects, particularly cancer risks. Sources of information included health providers, media, and social contact. By applying a meta-synthesis approach we demonstrate that these findings are broadly applicable across large groups of patients.


Although there are clear hazards associated with long-term HT use, many women view HT favorably for climacteric symptom relief. Media, as a source of information, is often valued as equivalent to health providers.


Hormone therapy has been one of the most broadly prescribed medications in recent memory. Although initially recommended for climacteric symptom control, there was a widespread understanding in the medical community that HT offered many favorable additional effects including cardiovascular and neurological protection [1], [2], [3]. because menopause naturally occurs when the ovaries begin decreasing production of estrogen and progesterone, and induced menopause occurs when the ovaries are surgically removed by bilateral oophorectomy or damaged by radiation or drugs, it usually takes 10 years for women to experience symptomatic changes. This is typically in a woman's late forties or early fifties, a time when lifestyle and other progressive diseases may become apparent. During this stage, many women experience physical and/or emotional symptoms [4], [5]. For some, symptoms related to menopause importantly impact their daily personal, professional, and social lives, resulting in a desire to reduce any adverse symptoms [6], [7].

With widespread support of HT for broad health benefits, single small trials or observational studies did not provide sufficient evidence to change the larger medical opinion. A large observational study, the Heart and Estrogen/progestin Replacement Study (HERS) [8] concluded that during 4.1 years of follow-up, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of coronary heart disease (CHD) events in postmenopausal women with established coronary disease; on the contrary, it increased the rate of thromboembolic events and gallbladder disease. In 2002, the Women's Health Initiative (WHI) randomized trial involving over 26,000 women [9] was stopped early due to increased risks of invasive breast cancer, pulmonary embolism, CHD and stroke when compared with placebo, confirming the findings of the HERS study [10]. A meta-analyses of observational studies published in 2002 indicated that HT was associated with long-term important harms, and a benefit only at osteoporosis prevention and climacteric relief [11]. The follow-up WHI study demonstrated HT was responsible for breast cancer and excess deaths directly attributed to breast cancer [12].

Despite evidence from these large studies, as many as 50% of physicians remain skeptical toward the evidence from WHI and HERS, citing concerns with study designs and patient populations [13]. Further, industry involvement in clinician and patient education has led to concern that benefits of HT are being unnecessarily promoted and harms are being reduced [14] . For this reason, it may be challenging for health care providers and menopausal women to make informed decisions on HT use. Although the use of HT has decreased [15], [16], there is uncertainty among obstetrician-gynecologists that it may be a viable treatment option for climacteric symptoms relief such as hot flashes, vaginal atrophy, osteoporosis and loss of Libido [17]. While studies have examined the knowledge and perceptions of physician and healthcare providers about the evidence for HT [13], [17], [18], no systematic review about the overall attitude or perception of menopausal women towards HT exist. In order to summarize women's attitudes and knowledge regarding HT use, we applied a meta-synthesis of published studies [19], [20], [21], a strategy that permits reviewers to identify common perceptions and beliefs and to determine the magnitude of these beliefs with some confidence.

Materials and Methods

Study approach

Our study approach is based on a two-step analysis of the studies. Firstly, we will identify the themes that are identified in qualitative studies. Secondly, we will determine the magnitude of these themes in broader populations by conducting a meta-analysis of surveys that report the themes. We have published on these methods extensively in the past [19], [20], [21], [22], [23], [24].

Eligibility criteria

For stage 1, we included two types of studies, qualitative studies and quantitative studies that used open-ended questions, allowing an unlimited number of participant responses. For stage 2, we included quantitative studies that report on the proportion of survey populations that affirm the issues raised in qualitative studies.

Eligible studies had to meet the following criteria: reported as an original research study and conducted in peri-menopausal women; contained information addressing attitude or knowledge towards HT; or information sources on HT. Studies that only compared the demographic characteristics between HT users and non-users; evaluated clinical outcomes; evaluated the proportion of HT use; or conducted within a specific population (eg. patients with breast cancer or cardiovascular diseases) were excluded.

Search strategy

Using a formal search strategy, MFT and YCT searched the following databases independently and in duplicate (from 07/2002 to 01/2011): MEDLINE, AMED, Alt Health Watch, CINAHL, Nursing and Allied Health Collection: Basic, and the Cochrane Database of Systematic Reviews. Our search strategy used permutations and combinations of the following terms: attitudes, perception, knowledge, behavior and belief, menopause, hormone treatment, HRT, qualitative, grounded theory, interview, questionnaire, cross-sectional and, survey. In addition, we supplemented this search by reviewing the bibliographies of key papers. We worked together to assess relevant studies for inclusion and only English language studies were included. MFT and YCT independently reviewed the abstracts and chose the full articles after discussion.

Data abstraction and validity assessment

MFT and HFS independently extracted data and appraised the validity. Disagreements were resolved by a third reviewer (PW). We extracted data on the methods of the studies using a modified checklist to assess internal validity [21] [25]. Quantitative studies were not scored as no accepted criteria exist for judging quality. A coding template to categorize key perceptions towards HT was developed iteratively during an initial review. This template consisted of the mutually exclusive headings listed as the positive factors that enable women to use; the negative factors that enable women to use; women' individual characteristics when making the decision and information sources of HT.

We then read all available surveys to determine whether they asked questions broadly representative of the themes identified in the qualitative studies. Data were regarded eligible for inclusion in the meta-analysis if the study reported proportions of respondents.

Statistical analyses

We used the κ statistic to measure chance-adjusted agreement between reviewers for study eligibility. When information on proportions of respondents was available from the quantitative studies, we calculated weighted proportions of studies using the Freeman-Tukey method [26]. We calculated an overall estimate of effect by pooling the proportions of each quantitative study by applying a random-effects model, with 95% Confidence Intervals (CI) and lower CI truncated at zero. We assessed heterogeneity of proportions visually as pooling proportions always results in large estimates of heterogeneity and statistical techniques do not yet exist to interpret the extent of real between-study heterogeneity for proportions [27]. We used Stats Direct for all statistical procedures.


Our search identified 220 relevant abstracts. There was good (κ = 0.64) agreement between MFT and YCT on choosing the final 77 applicable full-text studies for potential inclusion. Of these studies, 40 were excluded for various reasons, leaving 37 studies [5], [7], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62] included in our analyses (See figure 1).

Figure 1
Flow diagram of included studies.

We included eleven qualitative studies [40], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62] and 27 quantitative studies [7], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [63], reporting 31 independent studies. One study [40] included both qualitative and quantitative study. Table 1 shows the characteristics of the populations in the qualitative studies and Table 2 shows the methodology of these studies. Among these, 4 studies [40], [56], [60], [62] used focus groups (n = 248), five [53], [54], [57], [58], [59] used semi-structured interviews (n = 151), one [61] used both focus group and semi-structured interviews (n = 40) and one [55] used mainly open-ended questioning (n = 127). The attitudes identified towards HT are listed in Table 3.

Table 1
Study characteristics of qualitative study.
Table 2
Reporting criteria of qualitative studies.
Table 3
Attitude towards HT in qualitative studies.

The characteristics of all quantitative studies are listed in Table 4 and whether they used structured questionnaires or structured interviews (n = 39,251) to determine the attitude and acknowledgement of HT (see Table 5 for the details). Studies were completed in Asia [7], [28], [29], [35], [48], [51], [63], Europe [7], [32], [34], [36], [38], [39], [43], [44], [45], [46], [49], North America [7], [30], [31], [37], [41], [42], [50], [52], South America [33], Latin America [7], Oceania [47] and the Middle East [40].

Table 4
Characteristics of quantitative studies.
Table 5
Attitude towards HT identified in quantitative study.

To generalize the findings from qualitative studies, we pooled data for the factors reported in quantitative studies. From the pooled data we found that 47% (95%:34–60%) of participants perceived that HT was effective for climacteric symptoms, 26% (95% 15–40%) perceived that HT could be used in osteoporosis prevention and 33%(19%–48%) thought the benefits of HT outweigh the risks.

Thirty-one percent (95%CI: 18–46%) were aware of potential adverse events of HT, 37% (95%: 21–54%) aware HT may cause cancer and 14% (95%: 3–31% thought the risks of HT overweigh its benefit. Thirty-four percent (95%CI: 21–48%) thought it was unnecessary to use HT as the menopause-related symptoms were tolerable; 35% (95%CI: 24–47%) of respondents felt that the current evidence on HT was uncertain and 49%(95%CI: 22–76%) mentioned that they had no knowledge about HT.

For information sources, forty-three percent (95%CI: 26–60%) obtained menopause- and HT related information from media including TV, internet, magazines, and newspapers, while 47% (95%CI: 25–70) obtained information from their health care provider and 40% (95%CI: 17–65%) from their work or social contacts. No knowledge of HT was evaluated in 7 studies, and 5 of them was conducted in developing countries,. We found visible heterogeneity in all pooled analyses, which we explain by our a priori hypotheses that findings from developed countries differ from developing countries in terms of knowledge. Figure 2 shows the pooled proportions of attitudes that were generated from the outcomes listed in Table 5.

Figure 2
Pooled proportions of quantitative studies.


In our current review, we summarized women's attitude and perceptions towards HT reported in studies published after the WHI and found somewhat low levels of concern about serious adverse events. In addition, with the development of information technology, we also found media sources share a similar status as healthcare and have become a commonly used form of information. Women in developing countries had lower levels of knowledge about HT than those in more developed settings. These findings are concerning for several reasons. First, many obstetrician-gynecologists have report they were unlikely to change their prescribing practice following the WHI [17]. And secondly, emerging evidence indicates sources of information on HT benefits and harms may be skewed according to the funding body supporting the messaging, potentially downplaying risks associated with HT [15].

There are both strengths and weaknesses to consider when interpreting our study. A novelty of our study is that we synthesized and conducted a meta-analysis based on issues raised in qualitative studies and then assessed the magnitude of these beliefs in larger populations by pooling the answers from the quantitative studies. We have used this approach several times previously on unrelated topics [19], [20], [21], [22], [23], [24] and have published its methodological assumptions [20], [22]. Limitations of our study lie most inherently in the reporting biases presented in the included qualitative studies. Unlike protocol driven studies, such as randomized trials, where the outcomes should be established prior to the conduct of the study, one cannot determine what issues will be conclusively raised in qualitative studies. Thus, it is possible that some issues raised by participants are not reported in the final manuscripts. For that reason, we believe our approach is specific but not necessarily sensitive, our approach to pooling utilized proportions, an infrequently used metric to apply meta-analysis to. Although several methods of weighting proportions exist, we used the Freeman-Tukey method as we have evaluated its performance previously in meta-analysis [23], [64]. The choice of weighting proportions approach does not change the results of a meta-analysis importantly. We assessed heterogeneity visually and explained heterogeneity using a priori explanations of heterogeneity, specifically, geographic location of the study. Common methods of assessing heterogeneity do not perform well with proportions and appear to overestimate heterogeneity even when it is low [27].

Although in 2011, the use widespread use of HT seems misguided, HT has been broadly applied in clinical medicine for several decades. There is, however, consensus that HT is effective at climacteric symptoms reduction and osteoporosis prevention [65], [66]. Although many women benefit from intermittent HT use, the concerns about longer-term adverse events frequently outweigh the short term benefits. In 2005, the boards of the international, the Asian pacific, the European and the North American menopause society conducted post-hoc analyses of the WHI trial and noted that advanced age of the participants was importantly associated with adverse events. Concern about adverse events has also diminished the use of HT. HT use has declined by up to 62% since the WHI [67], [68]. In addition to decreased HT use, several locations have witnessed a potentially associated decrease in breast cancers.

It is important to recognize that it is difficult for patients to make informed decisions as many people obtain their health information from the media, particularly the internet. The issue is that websites can be of variable quality and may promote anti-evidence-based information [69] or may diminish the risks of HT while highlighting the benefits, or vice versa. As healthcare providers, physicians should either initiate or engage in discussions raised by the patients about HT, and recognize that this is an important opportunity to guide patients to evidence-informed sources of information, such as National women's health Resource Center, a non-profit resource aimed at providing up-to-date information for women. For women requesting HT, physicians may consider informing women that climacteric symptoms may be short-lasting and benign, and should be aware of the balanced effectiveness and risks of HT based on their individual situations [4].

In conclusion, HT has important adverse events, especially towards breast, many menopausal women are uncertain about the benefits and risks of HT indeed. Sources of reliable information may be an important challenge for patients. As health care providers, it is important to discuss both the benefits and risks with women and make the decision based on their culture, personal experience and readiness, especially in the developing countries. Providing a standard protocol for administration of HT, routine follow-up health examinations and instituting health teaching prior to prescription may be reasonable steps to assure HT is appropriately used and women remain informed and protected.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This study was supported by the Bureau Level Research Projects of Shanghai Municipal Health Bureau (2008001), and by the 2009 Action Plan for Technology Innovation of Science and Technology Commission of Shanghai (09DJ1400404). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990;97:1080–1086. [PubMed]
2. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol. 1992;166:1986–1992. [PubMed]
3. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811. [PubMed]
4. Canderelli R, Leccesse LA, Miller NL, Unruh Davidson J. Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract. 2007;19:635–641. [PubMed]
5. Huang KE, Xu L, I NN, Jaisamrarn U. The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function. Maturitas. 2010;65:276–283. [PubMed]
6. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772–780. [PubMed]
7. Heinemann K, Rubig A, Strothmann A, Nahum GG, Heinemann LA. Prevalence and opinions of hormone therapy prior to the Women's Health Initiative: a multinational survey on four continents. J Womens Health (Larchmt) 2008;17:1151–1166. [PubMed]
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama. 1998;280:605–613. [PubMed]
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama. 2002;288:321–333. [PubMed]
10. International Heart Lung and Blood Institute. Available: http://wwwnhlbinihgov/about/factbook/chapter3htm.
11. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. Jama. 2002;288:872–881. [PubMed]
12. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. Jama. 2010;304:1684–1692. [PubMed]
13. Power ML, Anderson BL, Schulkin J. Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause. 2009;16:500–508. [PMC free article] [PubMed]
14. Fugh-Berman A, McDonald CP, Bell AM, Bethards CE, Scialli RA. Promotional Tone in Reviews of Menopausal Hormone Therapy After the Women's Health Initiative: An Analysis of Published Articles. PLoS Med. 2011;8:e100425. [PMC free article] [PubMed]
15. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. Jama. 2004;292:1983–1988. [PubMed]
16. Hoffmann M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas. 2005;52:11–17. [PubMed]
17. Power ML, Zinberg S, Schulkin J. A survey of obstetrician-gynecologists concerning practice patterns and attitudes toward hormone therapy. Menopause. 2006;13:434–441. [PubMed]
18. Rolnick SJ, Jackson J, Kopher R, Defor TA. Provider management of menopause after the findings of the Women's Health Initiative. Menopause. 2007;14:441–449. [PubMed]
19. Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, et al. Barriers to participating in an HIV vaccine trial: a systematic review. Aids. 2004;18:2235–2242. [PubMed]
20. Mills EJ, Montori VM, Ross CP, Shea B, Wilson K, et al. Systematically reviewing qualitative studies complements survey design: an exploratory study of barriers to paediatric immunisations. J Clin Epidemiol. 2005;58:1101–1108. [PubMed]
21. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7:141–148. [PubMed]
22. Mills E, Jadad AR, Ross C, Wilson K. Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol. 2005;58:1081–1088. [PubMed]
23. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438. [PMC free article] [PubMed]
24. Maslove DM, Mnyusiwalla A, Mills EJ, McGowan J, Attaran A, et al. Barriers to the effective treatment and prevention of malaria in Africa: A systematic review of qualitative studies. BMC Int Health Hum Rights. 2009;9:26. [PMC free article] [PubMed]
25. Borenstein M, Hedges L, Higgins JP, Rothstein H. Introduction to Meta-analysis. 2009. Wiley, Chichester.
26. Freeman MF, Turkey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950:607–611.
27. Borenstein M, Hedges L, Higgins JP, Rothstein H. 2009. Introduction to Meta-analysis.
28. Lam PM, Leung TN, Haines C, Chung TK. Climacteric symptoms and knowledge about hormone replacement therapy among Hong Kong Chinese women aged 40–60 years. Maturitas. 2003;45:99–107. [PubMed]
29. Kaur S, Walia I, Singh A. How menopause affects the lives of women in suburban Chandigarh, India. Climacteric. 2004;7:175–180. [PubMed]
30. Barber CA, Margolis K, Luepker RV, Arnett DK. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000–2002). J Womens Health (Larchmt) 2004;13:975–985. [PubMed]
31. Obermeyer CM, Reynolds RF, Price K, Abraham A. Therapeutic decisions for menopause: results of the DAMES project in central Massachusetts. Menopause. 2004;11:456–465. [PubMed]
32. Ekstrom H. Trends in middle-aged women's reports of symptoms, use of hormone therapy and attitudes towards it. Maturitas. 2005;52:154–164. [PubMed]
33. Filho AS, Soares JMJR, Arkader J, Maciel GA, Baracat EC. Attitudes and practices about postmenopausal hormone therapy among female gynecologists in Brazil. Maturitas. 2005;51:146–153. [PubMed]
34. Hovi SL, Hakama M, Veerus P, Rahu M, Hemminki E. Who wants to join preventive trials?–Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]. BMC Med Res Methodol. 2005;5:12. [PMC free article] [PubMed]
35. Chaopotong P, Titapant V, Boriboonhirunsarn D. Menopausal symptoms and knowledge towards daily life and hormone replacement therapy among menopausal women in Bangkok. J Med Assoc Thai. 2005;88:1768–1774. [PubMed]
36. Thunell L, Stadberg E, Milsom I, Mattsson LA. Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstet Gynecol Scand. 2005;84:395–401. [PubMed]
37. Bosworth HB, Bastian LA, Grambow SC, McBride CM, Skinner CS, et al. Initiation and discontinuation of hormone therapy for menopausal symptoms: results from a community sample. J Behav Med. 2005;28:105–114. [PubMed]
38. Genazzani AR, Schneider HP, Panay N, Nijland EA. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol. 2006;22:369–375. [PubMed]
39. Sveinsdottir H, Olafsson RF. Women's attitudes to hormone replacement therapy in the aftermath of the Women's Health Initiative study. J Adv Nurs. 2006;54:572–584. [PubMed]
40. Loutfy I, Abdel Aziz F, Dabbous NI, Hassan MH. Women's perception and experience of menopause: a community-based study in Alexandria, Egypt. East Mediterr Health J. 2006;12(Suppl 2):S93–106. [PubMed]
41. Twiss JJ, Wegner J, Hunter M, Kelsay M, Rathe-Hart M, et al. Perimenopausal symptoms, quality of life, and health behaviors in users and nonusers of hormone therapy. J Am Acad Nurse Pract. 2007;19:602–613. [PubMed]
42. Rigby AJ, Ma J, Stafford RS. Women's awareness and knowledge of hormone therapy post-Women's Health Initiative. Menopause. 2007;14:853–858. [PubMed]
43. Uncu Y, Alper Z, Ozdemir H, Bilgel N, Uncu G. The perception of menopause and hormone therapy among women in Turkey. Climacteric. 2007;10:63–71. [PubMed]
44. Castelo-Branco C, Ferrer J, Palacios S, Cornago S, Peralta S. Spanish post-menopausal women's viewpoints on hormone therapy. Maturitas. 2007;56:420–428. [PubMed]
45. Lindh-Astrand L, Brynhildsen J, Hoffmann M, Liffner S, Hammar M. Attitudes towards the menopause and hormone therapy over the turn of the century. Maturitas. 2007;56:12–20. [PubMed]
46. Lindh-Astrand L, Brynhildsen J, Hoffmann M, Kjellgren KI, Hammar M. Knowledge of reproductive physiology and hormone therapy in 53- to 54-year-old Swedish women: a population-based study. Menopause. 2007;14:1039–1046. [PubMed]
47. Deeks A, Zoungas S, Teede H. Risk perception in women: a focus on menopause. Menopause. 2008;15:304–309. [PubMed]
48. Malik HS. Knowledge and attitude towards menopause and hormone replacement therapy (HRT) among postmenopausal women. J Pak Med Assoc. 2008;58:164–167. [PubMed]
49. Donati S, Cotichini R, Mosconi P, Satolli R, Colombo C, et al. Menopause: knowledge, attitude and practice among Italian women. Maturitas. 2009;63:246–252. [PubMed]
50. Huston SA, Jackowski RM, Kirking DM. Women's trust in and use of information sources in the treatment of menopausal symptoms. Womens Health Issues. 2009;19:144–153. [PubMed]
51. Jassim GA, Al-Shboul QM. Knowledge of Bahraini women about the menopause and hormone therapy: implications for health-care policy. Climacteric. 2009;12:38–48. [PubMed]
52. Simon JA, Reape KZ. Understanding the menopausal experiences of professional women. Menopause. 2009;16:73–76. [PubMed]
53. Ballard K. Understanding risk: women's perceived risk of menopause-related disease and the value they place on preventive hormone replacement therapy. Fam Pract. 2002;19:591–595. [PubMed]
54. Cifcili SY, Akman M, Demirkol A, Unalan PC, Vermeire E. “I should live and finish it”: a qualitative inquiry into Turkish women's menopause experience. BMC Fam Pract. 2009;10:2. [PMC free article] [PubMed]
55. French LM, Smith MA, Holtrop JS, Holmes-Rovner M. Hormone therapy after the Women's Health Initiative: a qualitative study. BMC Fam Pract. 2006;7:61. [PMC free article] [PubMed]
56. Hepworth J, Paine B, Miles H, Marley J, MacLennan A. The willingness of women to participate in a long-term trial of hormone replacement therapy: A qualitative study using focus groups. Psychology, Health & Medicine. 2002;7:469–476.
57. Hyde A, Nee J, Drennan J, Butler M, Howlett E. Hormone therapy and the medical encounter: a qualitative analysis of women's experiences. Menopause. 2010;17:344–350. [PubMed]
58. Kolip P, Hoefling-Engels N, Schmacke N. Attitudes toward postmenopausal long-term hormone therapy. Qual Health Res. 2009;19:207–215. [PubMed]
59. Nekhlyudov L, Bush T, Bonomi AE, Ludman EJ, Newton KM. Physicians' and women's views on hormone therapy and breast cancer risk after the WHI: a qualitative study. Women Health. 2009;49:280–293. [PubMed]
60. Shelton AJ, Lees E, Groff JY. Perceptions of hormone replacement therapy among African American women. J Health Care Poor Underserved. 2002;13:347–359. [PubMed]
61. Walter FM, Britten N. Patients' understanding of risk: a qualitative study of decision-making about the menopause and hormone replacement therapy in general practice. Fam Pract. 2002;19:579–586. [PubMed]
62. Welton A, Hepworth J, Collins N, Ford D, Knott C, et al. Decision-making about hormone replacement therapy by women in England and Scotland. Climacteric. 2004;7:41–49. [PubMed]
63. Huang KE, Xu L, I NN, Jaisamrarn U. The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function. Maturitas. 2010;65:276–283. [PubMed]
64. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Jama. 2006;296:679–690. [PubMed]
65. Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10:181–194. [PubMed]
66. Society CM. clinial guideline of hormone replacement therapy at the late menopusal transition and postmenopause. Chin J Obstet Gynecol. 2010;45:635–638.
67. Allemand H, Seradour B, Weill A, Ricordeau P. [Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend]. Bull Cancer. 2008;95:11–15. [PubMed]
68. Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat. 2009;118:425–432. [PubMed]
69. Keelan J, Pavri-Garcia V, Tomlinson G, Wilson K. YouTube as a source of information on immunization: a content analysis. Jama. 2007;298:2482–2484. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...